Marion Bennie

List of Publications by Year
in descending order

84 papers	**1,707** citations	361045 **20** h-index	344852 **36** g-index
86 all docs	**86** docs citations	**86** times ranked	**2408** citing authors

#	Article	IF	Citations
1	Efficacy of Mobile Apps to Support the Care of Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. JMIR MHealth and UHealth, 2017, 5, e4.	1.8	223
2	Data Resource Profile: The Scottish National Prescribing Information System (PIS). International Journal of Epidemiology, 2016, 45, 714-715f.	0.9	104
3	Risk of AKI with Gentamicin as Surgical Prophylaxis. Journal of the American Society of Nephrology: JASN, 2014, 25, 2625-2632.	3.0	100
4	Dabigatran â€" a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in Pharmacology, 2013, 4, 39.	1.6	75
5	Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 469-482.	0.7	74
6	Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 125-130.	0.7	72
7	Factors influencing national implementation of innovations within community pharmacy: a systematic review applying the Consolidated Framework for Implementation Research. Implementation Science, 2019, 14, 21.	2.5	60
8	Data feedback and behavioural change intervention to improve primary care prescribing safety (EFIPPS): multicentre, three arm, cluster randomised controlled trial. BMJ, The, 2016, 354, i4079.	3.0	52
9	Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. British Journal of Clinical Pharmacology, 2019, 85, 422-431.	1.1	43
10	Risk-factors for methadone-specific deaths in Scotland's methadone-prescription clients between 2009 and 2013*. Drug and Alcohol Dependence, 2016, 167, 214-223.	1.6	36
11	Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Medicine, 2014, 12, 98.	2.3	35
12	â€˜Lean'™, new technologies and employment in public health services: employees' experiences in the National Health Service. International Journal of Human Resource Management, 2014, 25, 2941-2956.	3.3	34
13	A point prevalence survey of antimicrobial utilisation patterns and quality indices amongst hospitals in South Africa; findings and implications. Expert Review of Anti-Infective Therapy, 2021, 19, 1353-1366.	2.0	34
14	HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY. International Journal of Technology Assessment in Health Care, 2017, 33, 279-287.	0.2	32
15	Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 655-666.	0.7	32
16	Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies. Pharmacoepidemiology and Drug Safety, 2017, 26, 1378-1386.	0.9	31
17	Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. Applied Health Economics and Health Policy, 2020, 18, 5-16.	1.0	31
18	Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. Journal of Comparative Effectiveness Research, 2014, 3, 41-51.	0.6	25

#	Article	IF	Citations
19	Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace, 2021, 23, 1722-1730.	0.7	24
20	Use of text-mining methods to improve efficiency in the calculation of drug exposure to support pharmacoepidemiology studies. International Journal of Epidemiology, 2018, 47, 617-624.	0.9	23
21	Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil. Applied Health Economics and Health Policy, 2018, 16, 697-709.	1.0	23
22	Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. European Heart Journal, 2022, 43, 3528-3538.	1.0	22
23	Statin use in Brazil: findings and implications. Current Medical Research and Opinion, 2018, 34, 1809-1817.	0.9	21
24	Introduction to drug utilization research. , 2016, , 1-12.		20
25	The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil. PLoS ONE, 2018, 13, e0199446.	1.1	19
26	A national, multicentre, web-based point prevalence survey of antimicrobial use and quality indices among hospitalised paediatric patients across South Africa. Journal of Global Antimicrobial Resistance, 2022, 29, 542-550.	0.9	19
27	The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil. Pharmacoeconomics, 2018, 36, 161-173.	1.7	17
28	Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine. Expert Review of Vaccines, 2018, 17, 1123-1133.	2.0	16
29	A cross-sectional survey of the pharmacy workforce in general practice in Scotland. Family Practice, 2020, 37, 206-212.	0.8	16
30	Realâ€world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish populationâ€based study. British Journal of Clinical Pharmacology, 2020, 86, 2349-2361.	1.1	16
31	Development of a web-based application to improve data collection of antimicrobial utilization in the public health care system in South Africa. Hospital Practice (1995), 2021, 49, 184-193.	0.5	16
32	Comparison of drug prescribing before and during the <scp>COVID</scp>â€19 pandemic: A crossâ€national European study. Pharmacoepidemiology and Drug Safety, 2022, 31, 1046-1055.	0.9	16
33	Effective Delivery of Pharmaceutical Palliative Care: Challenges in the Community Pharmacy Setting. Journal of Palliative Medicine, 2012, 15, 317-321.	0.6	15
34	Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence. Journal of Comparative Effectiveness Research, 2019, 8, 535-547.	0.6	15
35	Generic atypical antipsychotic drugs in Belgium: their influence and implications. Journal of Comparative Effectiveness Research, 2013, 2, 551-561.	0.6	14
36	Cumulative and temporal associations between antimicrobial prescribing and community-associatedClostridium difficileinfection: population-based caseâ€"control study using administrative data. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw528.	1.3	14

#	Article	IF	Citations
37	Assessment of adherence to drug treatment in database research. , 2016, , 369-380.		14
38	Potential to Enhance the Prescribing of Generic Drugs in Patients with Mental Health Problems in Austria; Implications for the Future. Frontiers in Pharmacology, 2012, 3, 198.	1.6	13
39	Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. Journal of Comparative Effectiveness Research, 2016, 5, 539-549.	0.6	13
40	A literature review of human factors and ergonomics within the pharmacy dispensing process. Research in Social and Administrative Pharmacy, 2020, 16, 637-645.	1.5	13
41	Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study. Current Medical Research and Opinion, 2020, 36, 677-686.	0.9	13
42	Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. International Journal of Clinical Practice, 2013, 67, 170-180.	0.8	12
43	Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands. Pharmacoepidemiology and Drug Safety, 2020, 29, 296-305.	0.9	12
44	Ongoing activities to influence the prescribing of proton pump inhibitors within the Scottish National Health Service: their effect and implications. GaBI Journal, 2018, 7, 142-151.	0.4	12
45	Effective Feedback to Improve Primary Care Prescribing Safety (EFIPPS) a pragmatic three-arm cluster randomised trial: designing the intervention (ClinicalTrials.gov registration NCT01602705). Implementation Science, 2014, 9, 133.	2.5	11
46	Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study. BMJ Open, 2019, 9, e027059.	0.8	10
47	Cost burden of Clostridioides difficile infection to the health service: A retrospective cohort study in Scotland. Journal of Hospital Infection, 2020, 106, 554-561.	1.4	10
48	Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?. Quality in Primary Care, 2013, 21, 7-15.	0.8	10
49	Use of record linkage to evaluate treatment outcomes and trial eligibility in a real‑world metastatic prostate cancer population in Scotland. Pharmacoepidemiology and Drug Safety, 2020, 29, 653-663.	0.9	9
50	Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysis. British Journal of Clinical Pharmacology, 2021, 87, 1129-1140.	1.1	9
51	Protocol for the Effective Feedback to Improve Primary Care Prescribing Safety (EFIPPS) study: a cluster randomised controlled trial using ePrescribing data. BMJ Open, 2012, 2, e002359.	0.8	8
52	Application of process mapping to understand integration of high risk medicine care bundles within community pharmacy practice. Research in Social and Administrative Pharmacy, 2018, 14, 944-950.	1.5	8
53	Optimizing carbapenem use through a national quality improvement programme. Journal of Antimicrobial Chemotherapy, 2018, 73, 2223-2230.	1.3	8
54	Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within a resource-constrained environment in the Scottish national health service: findings and implications. Expert Review of Respiratory Medicine, 2019, 13, 679-689.	1.0	8

#	Article	IF	Citations
55	Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet. Expert Review of Clinical Pharmacology, 2020, 13, 925-934.	1.3	8
56	Medication safety in primary careâ€"from measurement to action. Drug and Therapeutics Bulletin, 2021, 59, 24-28.	0.3	8
57	Measures to enhance angiotensin-receptor blocker prescribing efficiency in Belgium following generic losartan: impact and implications for the future. Journal of Pharmaceutical Health Services Research, 2013, 4, 173-181.	0.3	7
58	Managed introduction of new drugs. , 2016, , 210-221.		7
59	Developing a Model for Pharmaceutical Palliative Care in Rural Areasâ€"Experience from Scotland. Pharmacy (Basel, Switzerland), 2017, 5, 6.	0.6	7
60	Improving prescribing through big data approachesâ€"Ten years of the Scottish Prescribing Information System. British Journal of Clinical Pharmacology, 2020, 86, 250-257.	1.1	6
61	What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed methods approach in prostate cancer. Supportive Care in Cancer, 2022, 30, 3141-3150.	1.0	5
62	An introduction to adherence research. , 2016, , 355-360.		4
63	Impact of regulatory safety notices on valproate prescribing and pregnancy outcome among women of child-bearing potential in Scotland: a population-based cohort study. BMJ Open, 2022, 12, e058312.	0.8	4
64	What patient assessment skills are required by pharmacists prescribing systemic anti-cancer therapy? A consensus study. Journal of Oncology Pharmacy Practice, 2019, 25, 1933-1944.	0.5	3
65	Development and evaluation of a national gentamicin and vancomycin quality improvement programme. Journal of Antimicrobial Chemotherapy, 2020, 75, 1998-2003.	1.3	3
66	Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis. Pharmacoepidemiology and Drug Safety, 2021, 30, 482-491.	0.9	3
67	Development of a primary care pharmacy outcomes framework: An umbrella literature review. Research in Social and Administrative Pharmacy, 2021, , .	1.5	3
68	Retrospective cohort study to evaluate medication use in patients hospitalised with COVID-19 in Scotland: protocol for a national observational study. BMJ Open, 2021, 11, e054861.	0.8	3
69	Survey to identify research priorities for primary care in Scotland during and following the COVID-19 pandemic. BMJ Open, 2022, 12, e056817.	0.8	3
70	Residual effect of community antimicrobial exposure on risk of hospital onset healthcare-associated Clostridioides difficile infection: a caseâ€"control study using national linked data. Journal of Hospital Infection, 2019, 103, 259-267.	1.4	2
71	A Bayesian hierarchical approach for multiple outcomes in routinely collected healthcare data. Statistics in Medicine, 2020, 39, 2639-2654.	0.8	2
72	Competencies required for General Practice Clinical Pharmacists providing the Scottish Pharmacotherapy Service: A modified eDelphi study. Health and Social Care in the Community, 2021, 29, e328-e337.	0.7	2

#	Article	IF	Citations
73	Implementation of pharmacist-led services in primary care: A mixed-methods exploration of pharmacists'€™ perceptions of a national educational resource package. Pharmacy Practice, 2021, 19, 2440.	0.8	2
74	Integrating the community pharmacist into the diabetes team: evaluation of a new care model for patients with Type 2 diabetes mellitus. International Journal of Pharmacy Practice, 2011, 9, 60-60.	0.3	1
75	Drug utilization and health policy. , 2016, , 203-209.		1
76	Drug utilization research in the area of antibiotics. , 2016, , 270-283.		1
77	What are the competency requirements for clinical pharmacist verification of systemic anti-cancer therapy (SACT) prescribed within a clinical trial? A consensus study. Journal of Oncology Pharmacy Practice, 2022, 28, 1524-1533.	0.5	1
78	Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide. PharmacoEconomics - Open, 2022, 6, 303-313.	0.9	1
79	Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice. Health Informatics Journal, 2022, 28, 146045822210770.	1.1	1
80	A qualitative study of the relationship between the <scp>S</scp>cottish <scp>M</scp>edicines <scp>C</scp>onsortium and their clinical experts. Journal of Evaluation in Clinical Practice, 2016, 22, 311-318.	0.9	0
81	Management of drugs in a health care system. , 2016, , 222-230.		0
82	A qualitative study on factors influencing the implementation of a Clostridium difficile risk prediction tool in the Scottish secondary care setting. Access Microbiology, 2020, 2, .	0.2	0
83	Pharmacists in primary care in Scotland: a mixed-methods exploration of pharmacists'€™ perceptions of a national educational resource package. International Journal of Pharmacy Practice, 2022, 30, i11-i11.	0.3	0
84	Pharmacists in primary care in Scotland: an exploration of competencies required for the provision of pharmacy services within general practice. International Journal of Pharmacy Practice, 2022, 30, i31-i32.	0.3	0